CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
-
Shotgun watch: LA fire evacuees guard against looters
-
Los Angeles fire deaths at 10 as National Guard called in
-
'Control freak' Swiatek describes shock and 'chaos' over doping ban
-
Vietnam jails ex-lawyer over Facebook posts
-
Sinner in dark over verdict as ATP says doping case 'run by the book'
-
US President-elect Trump to be sentenced for hush money conviction
-
AI comes down from the cloud as chips get smarter
-
Englishman Hall grabs share of Sony Open lead
-
Olympic champ Zheng says 'getting closer' to top-ranked Sabalenka
-
Tajikistan bets on giant dam to solve electricity crisis
-
Air tankers fight Los Angeles fires from frantic skies
-
Right-wing disinformation targets DEI, 'liberal' policies as LA burns
-
Osaka to play Australian Open after 'devastating' injury pullout
-
'Disruptor' Medvedev ready to bring down Sinner and Alcaraz
-
Atletico can seize La Liga lead as Osasuna visit
-
Navalny lawyers face long sentences in 'extremism' trial
-
Sinner declares innocence as ATP chief says doping case 'run by the book'
-
India's Kumbh Mela, world's largest religious gathering
-
India readies for mammoth Hindu festival of 400 million pilgrims
-
Uruguay bucks 2024 global warming trend
-
Last 2 years crossed 1.5C global warming limit: EU monitor
-
Asian markets drift lower as US jobs data looms
-
Sabalenka has 'target on her back' in pursuit of Australian Open 'history'
-
Croatia's populist president tipped for re-election
-
Veteran Monfils powers past teenager to reach 35th final
-
Los Angeles fires rage on as National Guard called in
-
Japan 'poop master' gives back to nature
-
UN watchdog says Australia violated asylum seekers' rights
-
Murray braced for Djokovic ire in coaching debut at Australian Open
-
At CES, AI-powered garbage trucks reduce battery fire risk
-
S. Korea presidential security chief urges 'no bloodshed' in Yoon arrest
-
Combustible Kyrgios says tennis 'a bit mundane' without him
-
US Supreme Court to hear TikTok ban case
-
Los Angeles Rams playoff game moved to Arizona over fires: NFL
-
Survivors patrol as looters prey on fire-wrecked Los Angeles
-
US 'Pizzagate' conspiracy theory gunman killed by police: media
-
ATP chief insists Sinner doping case 'run by the book'
-
Venezuela opposition claims elusive leader briefly detained in Caracas protest
-
Los Angeles fires rage on as US National Guard called in
-
Chad says 20 killed in bid to storm presidential palace
-
Musk promotes German far-right leader in latest European intervention
-
Inter Miami's Mascherano cools Neymar talk
-
Danish PM reaches out to Trump over Greenland remarks
-
Everton advance in FA Cup after Dyche dismissal
-
Maria Corina Machado: the face and fire of Venezuela's opposition
-
Venezuela's Machado freed after being 'taken away by force': opposition
-
Real Madrid defeat Mallorca to reach Clasico Spanish Super Cup final
-
Jackson seeks deep Ravens run as NFL playoffs begin
-
Los Angeles fires rage on as residents sift through 'death and destruction'
-
Returning Evenepoel expects to be 'in very good shape' for Tour de France
NYSE - LSE
CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis
CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative therapies for high incidence immuno-dermatological disorders, today announced the initiation of a Phase 2b dose-ranging trial for its CGB-500 product. This topical JAK inhibitor ointment, developed using CAGE Bio's proprietary ionic liquid technology, represents a potential breakthrough for low body surface area (BSA), moderate to severe atopic dermatitis (AD) condition.
CGB-500 delivers medicine directly through the skin, combining high efficacy with minimal systemic exposure. Results from the 2024 Phase 2a trial showed efficacy comparable to biologics, outperforming current best-in-class topical treatments while maintaining a significantly lower side-effect profile. Specifically, CGB-500 had an 8-week treatment success of 95% (IGA score of "0" or "1" and > 2 grade improvement ).
This larger Phase 2b trial (n=180) will focus on optimizing dosing regimens and further assessing the safety and efficacy of CGB-500. This pivotal step underscores CAGE Bio's commitment to addressing the unmet needs of patients with moderate to severe AD and low body surface area (BSA) involvement, where treatment speed and efficacy must be balanced with the cost of systemic exposure and side effects.
"CGB-500 offers a promising solution for patients seeking rapid and effective localized relief potentially avoiding systemic therapies and their associated side-effects" said Dr. Justin Ko MD, a board-certified dermatologist in San Francisco Bay Area.
"Our ionic liquid platform continues to demonstrate its potential in enabling highly effective and targeted topical therapies. With the Phase 2b trial now underway, we are one step closer to transforming how atopic dermatitis is treated," said Nitin Joshi, Ph.D., CEO of CAGE Bio.
Atopic dermatitis is a chronic inflammatory skin condition affecting millions globally. Patients with highly localized, moderate to severe symptoms face limited treatment options. CGB-500 seeks to fill this gap, offering a high efficacy alternative with dramatically lower systemic exposure.
CAGE Bio remains committed to advancing clinical programs that deliver transformative therapies (efficacy of a biologic with safety of a topical ) for immuno-dermatological disorders.
About CAGE Bio
CAGE Bio is a clinical-stage biotechnology company developing innovative localized therapies for immune-mediated dermatological conditions. Its proprietary ionic liquid technology ensures effective drug delivery to target areas with minimal systemic exposure, improving patient outcomes.
Phone: +1 (650) 996-1845
email. [email protected]
SOURCE: CAGE Bio Inc.
O.Norris--AMWN
